Navigation Links
New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed
Date:7/20/2009

CAPE TOWN, South Africa, July 20 /PRNewswire/ -- New data became available today at the 5(th) International AIDS Society Conference from ARTEN (Atazanavir/Ritonavir on a background of Tenofovir and Emtricitabine [Truvada(R)] versus Nevirapine). ARTEN is an open-label, multi-center and international non-inferiority clinical trial. It is the first large study to directly compare the efficacy and safety of nevirapine and ritonavir-boosted atazanavir (ATV/r) when combined with TDF/FTC, a modern backbone therapy commonly used with both nevirapine and ATV/r in clinical practice. All patients enrolled in the study had CD4+ cell counts as recommended in the prescribing information for nevirapine use (men <400 cells/mm3; women <250 cells/mm3). Nevirapine is marketed in the U.S. under the trademark name of Viramune(R) (nevirapine) tablets/oral suspension.

A total of 569 patients were in the study: 188 received once-daily nevirapine (400 mg), 188 received twice-daily nevirapine (200 mg) and 193 received ATV/r (300/100 mg once-daily). Nevirapine is not indicated for once-daily dosing. The safety and efficacy of once-daily dosing have not been established. All study participants also received tenofovir and emtricitabine (Truvada(R)).

The study's primary endpoint was virologic response at 48 weeks of treatment, with response defined as a viral load of <50 copies/mL measured at two consecutive visits prior to week 48 (i.e. suppression at weeks 24 and 36) and without subsequent rebound or change of therapy prior to week 48. In the primary analysis of the primary endpoint, the two nevirapine arms were combined. A non-inferiority endpoint with a two-tailed confidence interval of 5 percent within a 12 percent degree of certainty was applied. ARTEN follow-up is currently planned to continue for a total of 144 weeks.

"We're pleased to see th
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...,Nov.25/PRNewswire-FirstCall/--Abaxis,Inc.(Nasdaq:...of-carebloodanalysissystems,announcedtodaythatClin...sentatthe21stAnnualPiperJaffrayHealthCareConferenc...ncewillbeheldattheNewYorkPalaceHotelinNewYorkCity....uresandmarketsportablebloodanalysissystemsforusein...
(Date:11/25/2009)...v.25/PRNewswire/--AccordingtoMillenniumResearchGro...tintelligence,thenearly$3billionUSmarketfortraumaf...extfiveyearsdespitetherecenteconomicslowdown.MRG,s...ismarketwillremainhighlydynamicoverthenextfiveyear...eviouslyunderservedsegmentsofthetraumafixationmark...
(Date:11/25/2009)...Nov.25/PRNewswire/--CempraPharmaceuticalsInc.today...fexecutiveofficer,willpresentatthePiperJaffray21st...2009,atTheNewYorkPalaceHotelinNewYorkCity.Dr.Ferna...ntibioticclinicalprogramsforthetreatmentofdrug-res...armaceuticals ,, Foundedin2006,CempraPharmaceu...
Breaking Medicine Technology:US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3Cancer Advocacy Organization Confronts the Source of rBGH Demands Pharmaceutical Giant Eli Lilly Stop Milking Cancer 57914 1Cancer Advocacy Organization Confronts the Source of rBGH Demands Pharmaceutical Giant Eli Lilly Stop Milking Cancer 57914 2Will Jatropha Become a 26apos 3BDotCom Bubble 26apos 3B in Biofuel Industry 3F Leading to 2nd JatrophaWorld Africa Jatropha Webinar on 30 Sept 09 Ex 14196 1Will Jatropha Become a 26apos 3BDotCom Bubble 26apos 3B in Biofuel Industry 3F Leading to 2nd JatrophaWorld Africa Jatropha Webinar on 30 Sept 09 Ex 14196 2Brain Aneurysm Patients Have A New Voice With Brain Storms Blog 57908 1Brain Aneurysm Patients Have A New Voice With Brain Storms Blog 57908 2Brain Aneurysm Patients Have A New Voice With Brain Storms Blog 57908 3
.../ -- Asenapine -- an,investigational drug being de...unit of Akzo Nobel, for bipolar I disorder and,sch...e than placebo,in treating acute manic and mixed e...ing to new Phase III results, from a study,present...Annual,Meeting. , In the three-week study, patient...
... -, COLLEGEVILLE, Pa., May 21, 2007 /PRNewswire-Fi...afety and efficacy of,desvenlafaxine succinate, a ... being studied as a potential treatment for adults...ted today at the,2007 American Psychiatric Associa... Pharmaceuticals, a division of Wyeth . Results,fr...
Other Medicine Technology:Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 2Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 3Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 2New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 3New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 5New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 6New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 7New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 8
(Date:11/25/2009)...elleMedicalInc.,aleadingmanufacturerofbreastMRIcoi...newleadingedgeclinicalapplicationsonitsAegis(TM)me...alSocietyofNorthAmerica(RSNA)annualmeetinginChicag...nsleveragetheuniquehighqualityimagesgeneratedbySen...pleimagingmodalitiesformulti-parametricassessment....
(Date:11/25/2009)...TheBayAreaAirQualityManagementDistrictisissuingthe...rt forThursday,November26,2009whichbansburningwo...oorsandoutdoors. ,, "Cold,stillweatherwillcontr...ent,executiveofficeroftheAirDistrict."We,reaskingB...ndfellowcommunitymembersthisThanksgiving,andnottob...
(Date:11/25/2009)...of a collaboration between UCLA engineers and phys...10 million Americans who suffer from peripheral ar... the arteries, peripheral arterial disease, or PAD...d arteries reduce blood flow to the limbs. The con...se, heart attack and stroke, and its progression c...
(Date:11/25/2009)...treatment clinics to resume Monday, Nov. 30 , ..., 2009 -- Centegra Health System is continuing to ...t four Centegra Primary Care (CPC) vaccination cli.... The clinics are at CPC sites in Huntley, Woodsto...ollows: ,   From 4:30 to 7:30 p.m. Tue...
(Date:11/25/2009)...IONSkincare ®isproudtosupportGNC,seffortstora...St.Jude ThanksandGiving campaign,$1fromthepurchase...pBalm willbedonatedtoSt.Jude.Additionally,GNCcusto...heckoutatoneoftheir5,000+retaillocationsoratGNC.co...their2009 ThanksandGiving campaign. ,, "Wearede...
Breaking Medicine News(10 mins):Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4Health News:MISSION Skincare(R) Supports GNC's Efforts To Raise Money for St. Jude Children's Research Hospital(R) 2
... hormone released during act reinforces maternal b...- Mothers who breast-feed are less likely to negle..., In their study, the scientists followed 7,223 Au...reast-fed for less than four months were twice as ...
...ith a particular gene variant may be more likely t...n people without the gene, according to a study pu...eurology , the medical journal of the American Aca...rme, the most common type of brain cancer. People ...
... having a private well or septic system, and other... risk factors for bacterial intestinal infections ...o food, such as the current Salmonella outbreak ...ically termed as enteric infections. The new study...
...eased 19% to $80.8 Million and EPS Increased to $1...k Repurchase Program for up to One Million Shares ...ves, Inc. (Nasdaq: MTXX ), a healthcare company ...its fiscal 2009 third quarter and nine months ende...
...ing to its strong executive team, Halo Pharmaceuti...ston, a thirty-five year pharmaceutical industry v...evelopment. Al comes to Halo from a long and dist...n of Al to the Halo business development team is a...
...e, third of popular sweetened products showed trac... Almost half of tested samples of commercial high-...h was also found in nearly a third of 55 popular b...aced sugar as the sweetener in many beverages and ...
Other Medicine News:Health News:Moms Who Breast-Feed Less Likely to Neglect Child 2Health News:Was it the chicken salad or the swim? 2Health News:Was it the chicken salad or the swim? 3Health News:Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share 2Health News:Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share 3Health News:Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share 4Health News:Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share 5Health News:Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share 6Health News:Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share 7Health News:Halo Pharmaceutical Welcomes Al Rosenston as its Vice President, Business Development 2Health News:Study Finds High-Fructose Corn Syrup Contains Mercury 2
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
Medicine Products: